Avacta wellcashed and on track to begin clinical trial of first Affimer therapeutic next year

Avacta well-cashed and on track to begin clinical trial of first Affimer therapeutic next year

04:00 EDT 9 Apr 2019 | Proactive Investors

The first Affimer-based therapeutic is PD-L1 – a potential cancer treatment that helps the immune system to identify and attack cancer cells

More From BioPortfolio on "Avacta well-cashed and on track to begin clinical trial of first Affimer therapeutic next year"